March 10 (Reuters) - Vertex Pharmaceuticals Inc :
* VERTEX ANNOUNCES FDA FAST TRACK DESIGNATION AND INITIATION OF A PHASE 1/2 CLINICAL TRIAL FOR VX-880, A NOVEL INVESTIGATIONAL CELL THERAPY FOR THE TREATMENT OF TYPE 1 DIABETES
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* VERTEX ANNOUNCES FDA FAST TRACK DESIGNATION AND INITIATION OF A PHASE 1/2 CLINICAL TRIAL FOR VX-880, A NOVEL INVESTIGATIONAL CELL THERAPY FOR THE TREATMENT OF TYPE 1 DIABETES
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)